Axsome Therapeutics (NASDAQ:AXSM) Given Outperform Rating at William Blair

Axsome Therapeutics (NASDAQ:AXSM)‘s stock had its “outperform” rating reaffirmed by equities researchers at William Blair in a research report issued to clients and investors on Friday,RTT News reports.

Several other analysts also recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $133.00 target price on shares of Axsome Therapeutics in a report on Monday, January 13th. StockNews.com raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. HC Wainwright reissued a “buy” rating and set a $180.00 target price on shares of Axsome Therapeutics in a research note on Tuesday. Robert W. Baird lifted their target price on Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Finally, Truist Financial boosted their price target on shares of Axsome Therapeutics from $150.00 to $180.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, Axsome Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $130.69.

Axsome Therapeutics Trading Down 0.6 %

Axsome Therapeutics stock traded down $0.64 during mid-day trading on Friday, hitting $103.26. The company’s stock had a trading volume of 129,535 shares, compared to its average volume of 967,156. Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $105.00. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. The firm has a market capitalization of $5.00 billion, a PE ratio of -15.81 and a beta of 1.04. The stock’s fifty day moving average is $92.32 and its two-hundred day moving average is $89.80.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.38) by $0.04. The firm had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same period in the previous year, the firm earned ($1.32) EPS. On average, analysts anticipate that Axsome Therapeutics will post -4.73 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AXSM. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Axsome Therapeutics by 22.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after purchasing an additional 318 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new stake in Axsome Therapeutics in the second quarter valued at approximately $27,000. WCM Investment Management LLC boosted its holdings in shares of Axsome Therapeutics by 0.3% in the third quarter. WCM Investment Management LLC now owns 113,692 shares of the company’s stock valued at $10,191,000 after acquiring an additional 347 shares during the period. KBC Group NV grew its position in shares of Axsome Therapeutics by 40.5% during the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock worth $113,000 after acquiring an additional 385 shares during the last quarter. Finally, US Bancorp DE increased its holdings in shares of Axsome Therapeutics by 0.3% in the 3rd quarter. US Bancorp DE now owns 133,126 shares of the company’s stock valued at $11,964,000 after acquiring an additional 421 shares during the period. 81.49% of the stock is owned by institutional investors and hedge funds.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.